Cimzia®

certolizumab pegol

UCB Australia Pty Ltd

Level 1, 1155 Malvern Rd

Malvern, VIC, 3144

Ph: 03 9828 1800

 

Indication

Cimzia® is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

 

Recommended dosing of Cimzia® for adult patients with chronic plaque psoriasis

Loading dose – 400mg (given as 2 subcutaneous injections of 200mg each) at Weeks 0, 2 and 4.

Maintenance dose –  200mg every 2 weeks or 400mg every 2 weeks. A dose of 400mg every 2 weeks may be specifically considered in patients with an insufficient response to 200mg every 2 weeks or in patients with a body weight of 90kg and above.

 

Product Information can be accessed at Cimzia® Product Information

PBS Information: This product is not listed on the Schedule of Pharmaceutical Benefits for the treatment of moderate to severe chronic plaque psoriasis. Authority required for the treatment of severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. Refer to PBS Schedule for full authority information at www.pbs.gov.au

Consumer Medical Information can be accessed at Cimzia® Consumer Medical Information


PATIENT SUPPORT RESOURCES

 EVERYDAY SUPPORT PROGRAM

For information regarding the EVERYDAY SUPPORT PROGRAM please contact 1800 246 942

Download CIMZIA® INJECTING GUIDE


PHYSICIAN SUPPORT RESOURCES

COMPASSIONATE SUPPLY

Compassionate supply enquiries must be directed to the UCB Medical Department for consideration. To request compassionate supply of Cimzia® for your psoriasis patient please contact: 

Ms Chantelle Herzog

Medical Solutions Lead

Ph:  03 9828 1800

Mobile:  0439 635 335

Email: chantelle.herzog@ucb.com

 

AUDIOVISUAL MATERIAL

Cimzia® Mechanism of Action

CLINICAL PUBLICATIONS

CIMZIA® FOR PLAQUE PSORIASIS

CIMPACT Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79(2):266-276.e5.
CIMPASI Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).  J Am Acad Dermatol. 2018;79(2):302-314.e6.

CIMACT/ CIMPASI POOLED –

LONG TERM DATA

Blauvelt A, Paul C, van de Kerkhof P, et al. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies Br J Dermatol. 2020.

CIMZIA® FOR PSORIATIC ARTHRITIS

RAPID PSA Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48-55.
RAPID PSA –  FOUR YEAR DATA van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis RMD Open 2018;4:e000582.

 

CIMZIA® PHARMACOKINETIC STUDIES IN HUMAN PREGNANCY AND LACTATION

CRIB Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-233.
CRADLE Clowse ME, Förger F, Hwang C, et al.  Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890-1896.

DRUG AND SAFETY MEDICAL INFORMATION

For medical information requests please contact medicalinformationAU@ucb.com

To report an adverse event to a UCB product, please contact UCB Australia Patient Safety on ds.au@ucb.com or 03 9828 1800 option 3.


UCB KEY CONTACTS

HCP Partners

NSW/ACT
Shaunagh Corfield
0439 009 488

VIC/TAS/SA
Jo Ann Dunstan
0439 043 150

QLD
Vicki Fisher
0408 051 981

WA
Marie Hart
0409 142 139

 

AU-N-CZ-PSO-2100001, June 2021

Medical Science Liaisons

NSW/QLD/NT
Todd McDougall
0407 909 576

NSW/ACT/SA
Tracey Edwards
0457 863 952

VIC/TAS/WA
Maree Powell
0427 388 643